ATLANTA, GA – – (Globe Newswire – November 19, 2024) – – A shareholder class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ: HUMA). The lawsuit alleges that Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects, including allegations that: (1) the Company’s Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing; (2) the FDA’s review of the  Biologic License Application would be delayed while Humacyte remediated these deficiencies; and (3) as a result, there was a substantial risk to FDA approval of the acellular tissue engineered vessel (“ATEV”) for vascular trauma.

If you bought shares of Humacyte between May 10, 2024, and October 17, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/humacyte/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is January 17, 2025.